Teleflex Incorporated (NYSE:TFX) has been assigned an average rating of “Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $316.13.
Several equities research analysts have recently weighed in on TFX shares. Morgan Stanley increased their target price on shares of Teleflex from $295.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 2nd. Needham & Company LLC reiterated a “strong-buy” rating and set a $325.00 target price (up previously from $300.00) on shares of Teleflex in a research note on Friday, February 22nd. Zacks Investment Research upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Tuesday, February 26th. Barclays set a $287.00 target price on shares of Teleflex and gave the stock a “hold” rating in a research note on Friday, February 22nd. Finally, UBS Group increased their target price on shares of Teleflex to $350.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd.
In related news, VP John Deren sold 125 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $290.43, for a total value of $36,303.75. Following the completion of the sale, the vice president now owns 2,539 shares in the company, valued at $737,401.77. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Benson Smith sold 8,500 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $305.83, for a total transaction of $2,599,555.00. Following the completion of the sale, the director now owns 84,913 shares of the company’s stock, valued at approximately $25,968,942.79. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,176 shares of company stock valued at $8,375,760. 2.36% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of TFX. Meeder Asset Management Inc. acquired a new stake in shares of Teleflex during the 1st quarter valued at approximately $31,000. Exane Derivatives acquired a new stake in shares of Teleflex during the 4th quarter valued at approximately $41,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Teleflex during the 1st quarter valued at approximately $52,000. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teleflex by 17.7% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 239 shares of the medical technology company’s stock valued at $62,000 after acquiring an additional 36 shares during the period. Finally, Valeo Financial Advisors LLC lifted its position in shares of Teleflex by 42.2% during the 4th quarter. Valeo Financial Advisors LLC now owns 337 shares of the medical technology company’s stock valued at $87,000 after acquiring an additional 100 shares during the period. Institutional investors own 91.84% of the company’s stock.
Shares of TFX opened at $277.05 on Friday. Teleflex has a fifty-two week low of $226.02 and a fifty-two week high of $309.99. The stock has a market cap of $12.76 billion, a PE ratio of 27.98, a price-to-earnings-growth ratio of 2.03 and a beta of 1.07. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.39.
Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 21st. The medical technology company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.76 by $0.01. Teleflex had a net margin of 8.20% and a return on equity of 18.47%. The business had revenue of $641.60 million during the quarter, compared to the consensus estimate of $641.06 million. During the same quarter in the prior year, the firm earned $2.44 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Teleflex will post 11.03 EPS for the current year.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Further Reading: Balance Sheet
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.